<DOC>
	<DOCNO>NCT01577264</DOCNO>
	<brief_summary>This observational trial Rheumatoid Arthritis Crohn 's Disease patient treat Cimzia aim evaluate risk incidence Tuberculosis .</brief_summary>
	<brief_title>Certolizumab Pegol Treatment Patients With Active Rheumatoid Arthritis ( RA ) Crohn 's Disease ( CD )</brief_title>
	<detailed_description>This prospective non interventional study . Patients enrol study receive Cimzia prescription accord instruction use approve Russia within frame current standard clinical practice . The patient evaluate Screening Visit enrollment . A Baseline Visit schedule 28 day Screening Visit . Subsequent evaluation do routinely every 6 month .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients prescribe Cimzia Any contraindication accord Russian Summary Product Characteristic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>